Zhe Wang: DT2216’s Potential as a Targeted Therapy for MPN AML
Zhe Wang, Research Fellow at Cincinnati Children’s Hospital Medical Center, shared a recent article he and his colleagues co-authored on LinkedIn, adding:
“Thrilled our work on a promising therapy for high-risk leukemia is published in Blood!
We tackled post-MPN AML, a deadly cancer with survival often <12 months. We found this subtype uniquely depends on BCL-xL for survival.
Our study shows DT2216, a novel platelet-sparing PROTAC degrader targeting BCL-xL:
Effectively kills JAK2-mutant AML cells (cell lines, patient samples, iPSC models).
Reduces tumors in vivo.
Inhibits cancer stem cell growth, alone or combined with azacytidine.
This highlights DT2216’s potential as a much-needed targeted therapy for this challenging leukemia.
Deep gratitude to my mentors, co-authors and collaborators!”
Title: Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML
Authors: Zhe Wang, Anna Skwarska, Gowri Poigaialwar, Sovira Chaudhry, Alba Rodriguez-Meira, Pinpin Sui, Emmanuel Olivier, Yannan Jia, Varun Gupta, Warren Fiskus, Cassandra L. Ramage, Guangrong Zheng, Alexandra Schurer, Kira Gritsman, Eirini P. Papapetrou, Kapil Bhalla, Daohong Zhou, Adam J. Mead, Raajit K. Rampal, Jeffrey W. Tyner, Hussein A. Abbas, Naveen Pemmaraju, Qi Zhang Tatarata, Marina Konopleva
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023